FMP
Unicycive Therapeutics, Inc.
UNCY
NASDAQ
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
0.97 USD
-0.07 (-7.22%)
About
ceo
Dr. Shalabh K. Gupta M.D., MPA
sector
Healthcare
industry
Biotechnology
website
https://www.unicycive.com
exchange
NASDAQ
Description
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
CIK
0001766140
ISIN
US90466Y1038
CUSIP
90466Y103
Address
4300 El Camino Real
Phone
650 351 4495
Country
US
Employee
14
IPO Date
Jul 12, 2021
Key Executives
